Sysmex Corporation · TSE:6869
Sysmex — H1 FY2006 Earnings Presentation
22 slides from Sysmex's earnings presentation, November 2006

Slide 1: Half Year 2006 Business Results
A Unique & Global Healthcare Testing Company Half Year 2006 Business Results Financial Highlights and Future Opportunities Hisashi Ietsugu President and CEO SYSMEX CORPORATION

Slide 2: Contents
Contents Outline of Half Year 2006 Results Results and Future Plans in Each Segment ¾ Geographical segments ¾ R&D segments FY2006 Consolidated Earnings Forecast Forward-looking Statements This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysme

Slide 3: Summary of Consolidated Statement FY2006 H.Y.
Outline of Half Year 2006 Results Summary of Consolidated Statement FY2006 H.Y. (in billions of JPY) Exchange rate for FY2005 H.Y. : 50 10 US$1=¥109.5、EUR1=¥135.7 47.4 Exchange rate for FY 2006 H.Y. : 41.6 US$1= ¥115.4、EUR1=¥146.0 40 8 Profit&Loss Statement 36.2 Recorded Recorded excellent excel

Slide 4: Breakdown of Net Sales and Ordinary Income
Outline of Half Year 2006 Results Breakdown of Net Sales and Ordinary Income ※FX impact excluded from regional sales below Gross margin increased as ・Increased SG&A Fix impact a result of a 0.3% ・R&D expenses: Up improvement in cost ratio ¥0.39 billion up1.9 ・Increased SG&A in (in billions of JPY) (

Slide 5: Geographical Segment Information
Outline of Half Year 2006 Results Geographical Segment Information Japan <Including Korea and Taiwan> (in billions of JPY) (Net Sales to (Operating Income) Outside Customers) (Operating Eurpoe (Operating Icome) 35 30.3 6 Americas 27.9 Income) 15 (Net Sales to 3 30 25.5 10 1.5 11.8 (Net Sales to Outs

Slide 6: Breakdown of Balance Sheet (Consolidated)
Outline of Half Year 2006 Results Breakdown of Balance Sheet (Consolidated) Tangible fixed (in billions of JPY) Fixed assets assets Others 1.0 △0.2 Retained Up 0.83 Others earnings 0.82 Equity/Minority 0.37 interest Others 1.2 Current assets 3.1 Inventories 2.0 Up 4.0 △0.07 Liabilities Fixed Notes/A

Slide 7: Consolidated Cash Flow
Outline of Half Year 2006 Results Consolidated Cash Flow 5 (In billions of JPY) 4.3 4.2 4.2 2.0 1.2 0.43 0.09 0 △0.57 △0.63 △1.6 △3.6 △ 3.5 △5 Net Increase in Operating CF Investing CF Finacing CF Cash and Cash Equivalents 2005.3 H.Y. 2006.3 H.Y. 2007.3 H.Y. ※Net Increase in Cash and Cash Equivalent

Slide 8: New Products (to be) Released in FY2006
Results and Future Plans in Each Segment New Products (to be) Released in FY2006 Hematology segment Urinalysis segment Automated hematology Urine cell analyzer analyzers UF-1000i XS Series Target area: Worldwide Target area: Worldwide Launch: Feb. 2006 in Japan, Launch: Jun. 2006 in Europe, and

Slide 9: Americas: Sysmex's market recognition increasing
Results and Future Plans in Each Segment Americas Sysmex’s market recognition increasing! <Topics> ¾ Entered into an exclusive sales agreement with Midwest Health System, an affiliate of the US’s largest class hospital group HCA Automated hematology analyzers ¾ Experienced strong sales of the XT ser

Slide 10: Strategic Priorities in the Commercial Lab Market
Results and Future Plans in Each Segment Topics Strategic Priorities in the Commercial Lab Market 【 Assumed customer concerns 】 ¾ Study of customers' analyzer selection process Evaluation point Concerns Increased productivity Not Concerns ¾ Strengthening communication and gaining trust Footprint sav

Slide 11: Europe: Business steadily expanded by leveraging the Sysmex brand
Results and Future Plans in Each Segment Europe Business steadily expanded by leveraging the Sysmex brand <Topics> ¾ Saw strong sales of hematology analyzers through comprehensive proposal-oriented marketing ¾ Launched the system for rapid detection of breast cancer lymph node metastasis (April) ¾ E

Slide 12: China: Influenced by the medical industry's clean-up campaign
Results and Future Plans in Each Segment China Influenced by the medical industry’s “clean-up campaign” <Topics> ¾ Underwent cost suppression due to reduction of test expenses (insurance points) ¾ Experienced slow sales of instruments due to the medical industry’s “clean-up campaign” ¾ Earned strong

Slide 13: Current Status and Future Prospect of Chinese Market
Results and Future Plans in Each Segment Topics Current Status and Future Prospect of Chinese Market Background of the medical industry’s “clean-up campaign” and its impacts on Sysmex Qualitative change and <Negative impacts> expansion of targets z Hospitals refraining from purchasing in Chinese mar

Slide 14: AP: Business opportunities in India accelerated
Results and Future Plans in Each Segment AP Business opportunities in India accelerated <Topics> ¾ Strengthen the marketing structure in India (Established Sysmex India) 9 Established a reagent factory in India ¾ Strong sales of the automated hematology analyzer XS series ¾ Promoted the solution bus

Slide 15: Japan: Strengthened business worthy of a comprehensive supplier
Results and Future Plans in Each Segment Japan Strengthened business worthy of a comprehensive supplier <Topics> (in billions of JPY) (Net Sales to Outside (Operating ¾ Medical fee reimbursements decreased by 3.16% Japan Customers) Income) ¾ Received an increasing number of orders for large-scale 70

Slide 16: Outline of Techno Park
Results and Future Plans in Each Segment Outline of Techno Park ¾¾Land Landarea: area:approx. approx.72 72thousand thousandsquare squaremeters, meters,twice twiceas aslarge largeas asthe thepresent presentR&D R&Dbase base ¾¾New Newbuilding buildingstructures: structures:R&D R&Dbuilding building(10(1

Slide 17: Strategic Priorities in Strengthening R&D
Results and Future Plans in Each Segment Strategic Priorities in Strengthening R&D Risk Early Definitive Drug efficacy Prediction of diagnosis detection diagnosis prediction prognosis Source: Ministry of Economy, Trade and Industry Genetic analysis Genetic analysis Chip technology technology Necessa

Slide 18: Progress in R&D
Results and Future Plans in Each Segment Progress in R&D Research Clinical trial Application/ Launch NHI price Approval listing (Clinical study) (Clinical trial) Launched in the European market in April Rapid detection technology for Colon Breast Japan: in preparation for lymph node metastasis can

Slide 19: Current Status of Commercialization of Life Science
Results and Future Plans in Each Segment Current Status of Commercialization of Life Science Progress after the launch of the system for rapid detection Recognized as the highly of breast cancer lymph node metastasis added value testing Standardization of Market awareness activities methods to get (

Slide 20: FY2006 Consolidated Earnings Forecast
FY2006 Consolidated Earnings Forecast FY2006 Consolidated Earnings Forecast (Planned exchange rate: FY2006 Consolidated Earnings Forecast US$1= ¥115, EUR1= ¥145) ¾ Sales: ¥98 billion ¾ Operating income: ¥13.3 billion ¾ Net Income:¥ 8.2 billion ¾ Ratio of Ordinary income: 13.6% ¾ Ratio of Net Income

Slide 21: Projected Dividend for FY2006
FY2006 Consolidated Earnings Forecast Projected Dividend for FY2006 Interim Year-end Total dividend dividend FY2006 ¥16 ¥16 ¥32 ¥16 FY2005 ¥20 (including 2 yen ¥36 commemorative dividend) (Reference) Conversion to dividend ¥10 ¥16 ¥26 after share split (Note: Sysmex split its common shares on a 2 fo

Slide 22: Challenging the Frontiers of Healthcare Testing
Challenging the Frontiers of Healthcare Testing SYSMEX CORPORATION <Contact> IR & Corporate Communication Div. Phone: 81-078-265-0500 Email: info@sysmex.co.jp URL: http://www.sysmex.co.jp A Unique & Global Healthcare Testing Company END
Source: Internet Archive copy of sysmex.co.jp
More decks from Sysmex Corporation
Investor Presentation (November 2026)43 slides · Nov 10, 2026
Q1 FY2027 Earnings Presentation33 slides · Aug 7, 2026
Investor Presentation (2025)43 slides · 2025
FY2011 Earnings Presentation23 slides · May 10, 2012
FY2012 Earnings Presentation23 slides · May 10, 2012
9M FY2012 Earnings Presentation12 slides · Feb 3, 2012